

References

1. Office of National Statistics. General Register Office (2005) Edinburgh, Scotland; General Register Office (2005) Northern Ireland 2005.
2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987;257:3233-40.
3. Butler WJ, Ostrander LD, Jr., Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. *Am J Epidemiol* 1985;121:541-7.
4. Dawber TR, Meadors GF, Moore FE, Jr. Epidemiological approaches to heart disease: the Framingham Study. *Am J Public Health Nations Health* 1951;41:279-81.
5. Dyer AR, Stamler J, Paul O et al. Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. *J Chronic Dis* 1981;34:249-60.
6. Fager G, Wiklund O, Olofsson SO, Wilhelmsen L, Bondjers G. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. *Arteriosclerosis* 1981;1:273-9.
7. Kagan A, Harris BR, Winkelstein W, Jr. et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. *J Chronic Dis* 1974;27:345-64.
8. Keys A, Menotti A, Aravanis C et al. The seven countries study: 2,289 deaths in 15 years. *Prev Med* 1984;13:141-54.
9. Keys A. Coronary heart disease in seven countries. 1970. *Nutrition* 1997;13:250-2.
10. Kushi LH, Lew RA, Stare FJ et al. Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. *N Engl J Med* 1985;312:811-8.
11. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. *Lancet* 1986;2:933-6.
12. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. *Lancet* 1977;1:965-8.
13. Verschuren WM, Jacobs DR, Bloemberg BP et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. *JAMA* 1995;274:131-6.

14. Brensike JF, Levy RI, Kelsey SF et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. *Circulation* 1984;69:313-24.
15. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). *N Engl J Med* 1990;323:946-55.
16. Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990;336:129-33.
17. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? *Atherosclerosis* 1997;131:1-5.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;339:1349-57.
19. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;279:1615-22.
20. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation* 1998;97:946-52.
21. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999;282:2340-6.
22. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;352:20-8.
23. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335:1001-9.
24. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995;333:1301-7.
25. The 4S Study Group. . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383-9.
26. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *J Am Coll Cardiol* 2004;44:720-32.

27. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association *BMJ* 2000;320:705-8
28. De BG, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease and prevention in clinical practice. *Atherosclerosis* 2003;171:145-55.
29. Lichtenstein AH, Appel LJ, Brands M et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. *Arterioscler Thromb Vasc Biol* 2006;26:2186-91.
30. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. *Am J Clin Nutr* 1965;17:281-95.
31. Hegsted DM, Ausman LM, Johnson JA, Dallal GE. Dietary fat and serum lipids: an evaluation of the experimental data. *Am J Clin Nutr* 1993;57:875-83.
32. Turpeinen O. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. *Circulation* 1979;59:1-7.
33. Watts GF, Lewis B, Brunt JN et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). *Lancet* 1992;339:563-9.
34. Ornish D, Scherwitz LW, Billings JH et al. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA* 1998;280:2001-7.
35. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. *N Engl J Med* 1995;333:1308-12.
36. Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. *Am J Clin Nutr* 1999;69:403-10.
37. Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. *Eur J Clin Nutr* 2000;54:715-25.
38. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. *Am J Cardiol* 2000;86:46-52.
39. Cater NB, Garcia-Garcia AB, Vega GL, Grundy SM. Responsiveness of plasma lipids and lipoproteins to plant stanol esters. *Am J Cardiol* 2005;96:23D-8D.

40. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. *Metabolism* 1999;48:575-80.
41. Hallikainen M, Lyyra-Laitinen T, Laitinen T et al. Endothelial function in hypercholesterolemic subjects: Effects of plant stanol and sterol esters. *Atherosclerosis* 2006;188:425-32.
42. Homma Y, Ikeda I, Ishikawa T, Tateno M, Sugano M, Nakamura H. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial. *Nutrition* 2003;19:369-74.
43. Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. *Atherosclerosis* 2002;160:205-13.
44. Noakes M, Clifton PM, Doornbos AM, Trautwein EA. Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. *Eur J Nutr* 2005;44:214-22.
45. Salo P, Wester I. Low-fat formulations of plant stanols and sterols. *Am J Cardiol* 2005;96:51D-4D.
46. Vanhanen HT, Blomqvist S, Ehnholm C et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. *J Lipid Res* 1993;34:1535-44.
47. Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. *Clin Sci (Lond)* 1994;87:61-7.
48. Alhassan S, Reese KA, Mahurin J et al. Blood lipid responses to plant stanol ester supplementation and aerobic exercise training. *Metabolism* 2006;55:541-9.
49. Jauhiainen T, Salo P, Niittynen L, Poussa T, Korpela R. Effects of low-fat hard cheese enriched with plant stanol esters on serum lipids and apolipoprotein B in mildly hypercholesterolaemic subjects. *Eur J Clin Nutr* 2006;60:1253-7.
50. Miettinen TA, Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. *Atherosclerosis* 1994;105:217-26.
51. Nguyen TT, Dale LC, von BK, Croghan IT. Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial. *Mayo Clin Proc* 1999;74:1198-206.
52. Plat J, van Onselen EN, van Heugten MM, Mensink RP. Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of

margarines and shortenings enriched with plant stanol esters. *Eur J Clin Nutr* 2000;54:671-7.

53. Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. *Atherosclerosis* 2000;148:101-12.

54. Law M. Plant sterol and stanol margarines and health. *BMJ* 2000;320:861-4.

55. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. *Diabetologia* 1994;37:773-80.

56. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. *J Lipid Res* 1996;37:1776-85.

57. Lu K, Lee MH, Patel SB. Dietary cholesterol absorption; more than just bile. *Trends Endocrinol Metab* 2001;12:314-20.

58. Siperstein MD, Chalkoff IL, Reinhardt WO. C14-Cholesterol. V. Obligatory function of bile in intestinal absorption of cholesterol. *J Biol Chem* 1952;198:111-4.

59. Heinemann T, Kullak-Ublick GA, Pietruck B, von BK. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Comparison of sitosterol and sitostanol. *Eur J Clin Pharmacol* 1991;40 Suppl 1:S59-S63.

60. Lutjohann D, Bjorkhem I, Beil UF, von BK. Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. *J Lipid Res* 1995;36:1763-73.

61. Armstrong MJ, Carey MC. Thermodynamic and molecular determinants of sterol solubilities in bile salt micelles. *J Lipid Res* 1987;28:1144-55.

62. Ikeda I, Tanabe Y, Sugano M. Effects of sitosterol and sitostanol on micellar solubility of cholesterol. *J Nutr Sci Vitaminol (Tokyo)* 1989;35:361-9.

63. Nissinen M, Gylling H, Vuoristo M, Miettinen TA. Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion. *Am J Physiol Gastrointest Liver Physiol* 2002;282:G1009-G1015.

64. Hallikainen M, Sarkkinen E, Wester I, Uusitupa M. Short-term LDL cholesterol-lowering efficacy of plant stanol esters. *BMC Cardiovasc Disord* 2002;2:14.

65. Heinemann T, Axtmann G, von BK. Comparison of intestinal absorption of cholesterol with different plant sterols in man. *Eur J Clin Invest* 1993;23:827-31.

66. Ostlund RE, Jr., McGill JB, Zeng CM et al. Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans. *Am J Physiol Endocrinol Metab* 2002;282:E911-E916.

67. Plat J, Mensink RP. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. *Am J Cardiol* 2005;96:15D-22D.
68. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* 1999;69:30-42.
69. Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. *Am J Cardiol* 2006;98:633-40.